Bpifrance Life Sciences Venture (InnoBio)

Très fier d’annoncer la levée de 105 M€ d’Adcytherix, menée par Bpifrance à travers nos fonds Bpifrance Large Venture et Bpifrance Life Sciences Venture (InnoBio), aux côtés de Kurma Partners, Andera Partners, Angelini Ventures, et d’un consortium international d’investisseurs de tout premier plan. 👉 Adcytherix développe une nouvelle génération d’anticorps conjugués (ADC), intégrant des agents cytotoxiques innovants – une approche de rupture pour traiter des cancers aujourd’hui résistants aux thérapies existantes. Cette levée record pour une série A dans le domaine des ADC en Europe va permettre à la biotech marseillaise de conduire son premier candidat ADCX-020 vers les essais cliniques dès 2025, et de poursuivre le développement d’un portefeuille d’ADC propriétaires différenciés. Au-delà du financement, c’est une marque de confiance envers une équipe d’entrepreneurs et de chercheurs d’exception, menée par Jack Elands, qui met la science et la technologie au service de la vie. Avec cette opération, nous confirmons la volonté de Bpifrance d’accompagner la prochaine génération de leaders biopharmaceutiques français, en soutenant des innovations de rupture qui redéfiniront les standards mondiaux de la médecine de précision. Bravo à toute l’équipe d’Adcytherix et à nos partenaires investisseurs pour cette étape majeure ! 👏 #Innovation #HealthTech #DeepTech https://lnkd.in/eq9nM_vB

🚀 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗻𝗲𝘄𝘀 | 𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗣𝗵𝗮𝘀𝗲 𝟮 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗡𝗢𝗨𝗦-𝟮𝟬𝟵 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗶𝗻 𝗠𝗦𝗜-𝗛 𝗺𝗖𝗥𝗖! 🚀   We are proud to announce that our 𝗜𝗻𝗻𝗼𝗕𝗶𝗼 𝟮 portfolio company, Nouscom , will present positive Phase 2 results for its off-the-shelf immunotherapy 𝗡𝗢𝗨𝗦-𝟮𝟬𝟵 in combination with pembrolizumab, in patients with MSI-H metastatic colorectal cancer (mCRC) refractory to anti-PD-1 therapy, at the upcoming ESMO - European Society for Medical Oncology 𝟮𝟬𝟮𝟱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴.   𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 🔵 𝗡𝗢𝗨𝗦-𝟮𝟬𝟵 + 𝗽𝗲𝗺𝗯𝗿𝗼𝗹𝗶𝘇𝘂𝗺𝗮𝗯 has shown clinical activity and strong disease control in a difficult-to-treat population with limited options after anti-PD-1 resistance. 🔵 𝗢𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗥𝗮𝘁𝗲: 15% (3 partial responses), Disease Control Rate: 70%, Median PFS: 6.4 months. 🔵 𝗥𝗼𝗯𝘂𝘀𝘁 𝗶𝗺𝗺𝘂𝗻𝗲 𝗮𝗰𝘁𝗶𝘃𝗮𝘁𝗶𝗼𝗻 detected in 80% of patients; retreatment at 6 months induced strong, durable, and polytopic T cell responses. 🔵 𝗙𝗮𝘃𝗼𝗿𝗮𝗯𝗹𝗲 𝘀𝗮𝗳𝗲𝘁𝘆 𝗽𝗿𝗼𝗳𝗶𝗹𝗲 with no emerging findings. 🔵 NOUS-209 monotherapy is also advancing for cancer interception in 𝗟𝘆𝗻𝗰𝗵 𝗦𝘆𝗻𝗱𝗿𝗼𝗺𝗲, with a registration-enabling Phase 2/3 study in preparation.   𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: There remains a high unmet need for effective therapies that can overcome anti-PD-1 resistance and provide durable disease control in MSI-H mCRC. These results are promising and support the advancement of NOUS-209 as a new option for patients who have exhausted standard treatments.   𝗗𝗲𝘁𝗮𝗶𝗹𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁 𝗮𝗻𝗱 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝘁 𝗘𝗦𝗠𝗢: ◾ 𝗧𝗶𝘁𝗹𝗲: NOUS-209 immunotherapy with pembrolizumab for microsatellite instability high (MSI-H) metastatic colorectal cancer, refractory to anti-PD-1: Phase II trial results ◾𝗣𝗼𝘀𝘁𝗲𝗿 𝗡𝘂𝗺𝗯𝗲𝗿: 802P ◾𝗦𝗲𝘀𝘀𝗶𝗼𝗻: Colorectal Cancer Poster Session ◾𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗧𝗶𝗺𝗲/𝗣𝗹𝗮𝗰𝗲: Sunday, October 19 / 12:00–12:45 (CEST) / Hall 25 ◾The abstract is available on the ESMO website   𝗕𝗲𝘆𝗼𝗻𝗱 𝗠𝗦𝗜-𝗛 𝗺𝗖𝗥𝗖: We are excited by the overall positive clinical dataset emerging from the completed clinical trials of NOUS-209—not only in MSI-H mCRC patients, but also in Lynch Syndrome carriers, as shown in the Phase 1b/2 results presented earlier this year at AACR. These results reinforce our commitment to advancing NOUS-209 into a registration-enabling study for cancer interception in Lynch Syndrome carriers.   👏 Congratulations to the Nouscom team for this important milestone and for their commitment to advancing next-generation immunotherapies!   #Biotech #Immunotherapy #Oncology #Innovation #PortfolioSuccess #InnoBio2

🚀 𝗡𝗲𝘄 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 | 𝗕𝗽𝗶𝗳𝗿𝗮𝗻𝗰𝗲 𝗹𝗲𝗮𝗱𝘀 €𝟭𝟬𝟱𝗠 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 𝗶𝗻 𝗔𝗱𝗰𝘆𝘁𝗵𝗲𝗿𝗶𝘅! 🚀   We are excited to announce our participation as 𝗹𝗲𝗮𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗶𝗻 𝘁𝗵𝗲 €𝟭𝟬𝟱𝗠 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴 𝗼𝗳 Adcytherix, a pioneering biopharma company developing 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗱𝗿𝘂𝗴 𝗰𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲𝘀 (𝗔𝗗𝗖𝘀) with 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗽𝗮𝘆𝗹𝗼𝗮𝗱 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀.   𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 💠 €𝟭𝟬𝟱𝗠 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 led by Bpifrance (Bpifrance Large Venture & Bpifrance Life Sciences Venture (InnoBio)), with co-leads Kurma Partners, Andera Partners, and Angelini Ventures, followed by other prestigious new investors, Surveyor Capital (𝗖𝗶𝘁𝗮𝗱𝗲𝗹) and aMoon Fund, and with renewed participation from all existing shareholders, including Pontifax Venture Capital, Dawn Biopharma (𝗞𝗞𝗥), Pureos Bioventures and RA Capital Management.  💠 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗼𝗻: Funds will advance 𝗔𝗗𝗖𝗫-𝟬𝟮𝟬 to the clinic, with first IND/CTA filings expected by end of 2025. 💠 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: Adcytherix is building a portfolio of proprietary ADCs with new payload strategies, targeting cancers with high unmet needs. 💠 𝗘𝘅𝗽𝗲𝗿𝘁 𝘁𝗲𝗮𝗺: Founded by Jack Elands and Pontifax, with a leadership team and board of world-class ADC experts and investors. 💠 𝗚𝗹𝗼𝗯𝗮𝗹 𝗮𝗺𝗯𝗶𝘁𝗶𝗼𝗻: Headquartered in Marseille, France, with subsidiaries in the US and Netherlands.   𝗪𝗵𝘆 𝘄𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗲𝗱: Olivier Martinez, Senior Investment Director at Bpifrance commented: "𝘛𝘩𝘦 𝘤𝘢𝘭𝘪𝘣𝘦𝘳 𝘰𝘧 𝘵𝘩𝘦 𝘈𝘥𝘤𝘺𝘵𝘩𝘦𝘳𝘪𝘹 𝘵𝘦𝘢𝘮 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘲𝘶𝘢𝘭𝘪𝘵𝘺 𝘰𝘧 𝘪𝘵𝘴 𝘙&𝘋 𝘢𝘳𝘰𝘶𝘯𝘥 𝘯𝘦𝘸 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘱𝘢𝘺𝘭𝘰𝘢𝘥𝘴 𝘤𝘰𝘯𝘷𝘪𝘯𝘤𝘦𝘥 𝘶𝘴 𝘵𝘰 𝘭𝘦𝘢𝘥 𝘵𝘩𝘪𝘴 𝘚𝘦𝘳𝘪𝘦𝘴 𝘈 𝘳𝘰𝘶𝘯𝘥. 𝘛𝘩𝘦 𝘤𝘰𝘮𝘱𝘢𝘯𝘺 𝘪𝘴 𝘶𝘯𝘪𝘲𝘶𝘦𝘭𝘺 𝘱𝘰𝘴𝘪𝘵𝘪𝘰𝘯𝘦𝘥 𝘵𝘰 𝘢𝘥𝘷𝘢𝘯𝘤𝘦 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵𝘪𝘢𝘵𝘦𝘥 𝘈𝘋𝘊𝘴 𝘢𝘨𝘢𝘪𝘯𝘴𝘵 𝘤𝘢𝘯𝘤𝘦𝘳𝘴 𝘰𝘧 𝘩𝘪𝘨𝘩 𝘶𝘯𝘮𝘦𝘵 𝘯𝘦𝘦𝘥. 𝘞𝘦 𝘢𝘳𝘦 𝘵𝘳𝘶𝘭𝘺 𝘥𝘦𝘭𝘪𝘨𝘩𝘵𝘦𝘥 𝘵𝘰 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘑𝘢𝘤𝘬 𝘢𝘯𝘥 𝘩𝘪𝘴 𝘵𝘦𝘢𝘮 𝘪𝘯 𝘵𝘩𝘪𝘴 𝘯𝘦𝘸 𝘢𝘥𝘷𝘦𝘯𝘵𝘶𝘳𝘦, 𝘩𝘢𝘷𝘪𝘯𝘨 𝘢𝘭𝘳𝘦𝘢𝘥𝘺 𝘸𝘰𝘳𝘬𝘦𝘥 𝘤𝘭𝘰𝘴𝘦𝘭𝘺 𝘸𝘪𝘵𝘩 𝘩𝘪𝘮 𝘥𝘶𝘳𝘪𝘯𝘨 𝘩𝘪𝘴 𝘱𝘳𝘦𝘷𝘪𝘰𝘶𝘴 𝘴𝘶𝘤𝘤𝘦𝘴𝘴𝘧𝘶𝘭 𝘣𝘪𝘰𝘵𝘦𝘤𝘩 𝘷𝘦𝘯𝘵𝘶𝘳𝘦".   👏 Congratulations to the Adcytherix team and all co-investors for this record-breaking round and for advancing the future of oncology! Nicolas Dufourcq, Paul-François Fournier, Maïlys Ferrere, Laurent Higueret, Olivier Martinez, Antoine Mérien, Marine Choplain, Adrien de Saint Victor   #Biotech #Innovation #Oncology #ADC #VentureCapital #NewInvestment #Bpifrance #LargeVenture #InnoBio

🚀 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗡𝗲𝘄𝘀 | 𝗦𝘁𝗲𝗽 𝗣𝗵𝗮𝗿𝗺𝗮 𝗥𝗮𝗶𝘀𝗲𝘀 €𝟯𝟴𝗠 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 🚀   We are proud to announce that our 𝗜𝗻𝗻𝗼𝗕𝗶𝗼 𝟮 portfolio company, Step Pharma, has successfully completed a €𝟯𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴 𝗿𝗼𝘂𝗻𝗱!   This milestone will accelerate the clinical development of their lead asset, 𝗱𝗲𝗻𝗰𝗮𝘁𝗶𝘀𝘁𝗮𝘁, a first-in-class CTPS1 oral inhibitor, for the treatment of blood cancers, solid tumours and essential thrombocytemia. CTPS1 is a key component of the pyrimidine synthesis pathway for DNA synthesis and cell proliferation.   𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ▪️ €𝟯𝟴𝗠 𝗿𝗮𝗶𝘀𝗲𝗱 to fuel innovation in targeted cancer therapies ▪️ 𝗗𝗲𝗻𝗰𝗮𝘁𝗶𝘀𝘁𝗮𝘁: a first-in-class oral inhibitor of CTPS1 in clinical development ▪️ 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗶𝗻 𝗮 𝗽𝗿𝗼𝗱𝘂𝗰𝘁: three clinical programs (lymphoma, CTPS2-null solid tumours, essential thrombocythaemia) ▪️ 𝗡𝗲𝘄 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿: V-Bio Ventures leads the round, joined by historical investors Pontifax Venture Capital, Bpifrance Life Sciences Venture (InnoBio), Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures, and INSERM TRANSFERT INITIATIVE. ▪️ 𝗥𝗲𝗰𝗼𝗴𝗻𝗶𝘁𝗶𝗼𝗻: Dencatistat received orphan drug designation for T cell lymphoma (May 2025)   𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: Step Pharma’s approach — selectively inhibiting CTPS1 to kill cancer cells — could lead to a new highly selective, safe and effective treatment for several cancers.   Thibaut Roulon, Senior Investment Director at Bpifrance commented: "𝘞𝘪𝘵𝘩 𝘵𝘩𝘳𝘦𝘦 𝘪𝘯𝘥𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴 𝘣𝘦𝘪𝘯𝘨 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘵𝘦𝘴𝘵𝘦𝘥, 𝘋𝘦𝘯𝘤𝘢𝘵𝘪𝘴𝘵𝘢𝘵 𝘪𝘴 𝘢 𝘩𝘪𝘨𝘩𝘭𝘺 𝘱𝘳𝘰𝘮𝘪𝘴𝘪𝘯𝘨 𝘧𝘪𝘳𝘴𝘵-𝘪𝘯-𝘤𝘭𝘢𝘴𝘴 𝘥𝘳𝘶𝘨 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘵𝘰 𝘣𝘦𝘤𝘰𝘮𝘦 𝘢 ”𝘱𝘪𝘱𝘦𝘭𝘪𝘯𝘦 𝘪𝘯 𝘢 𝘱𝘳𝘰𝘥𝘶𝘤𝘵”. 𝘛𝘩𝘪𝘴 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘯𝘨 𝘸𝘪𝘭𝘭 𝘦𝘯𝘢𝘣𝘭𝘦 𝘚𝘵𝘦𝘱 𝘗𝘩𝘢𝘳𝘮𝘢 𝘵𝘰 𝘤𝘰𝘮𝘱𝘭𝘦𝘵𝘦 𝘵𝘩𝘦 𝘰𝘯𝘨𝘰𝘪𝘯𝘨 𝘱𝘩𝘢𝘴𝘦 1 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘢𝘯𝘥 𝘧𝘶𝘳𝘵𝘩𝘦𝘳 𝘢𝘴𝘴𝘦𝘴𝘴 𝘵𝘩𝘦 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺 𝘰𝘧 𝘋𝘦𝘯𝘤𝘢𝘵𝘪𝘴𝘵𝘢𝘵 𝘪𝘯 𝘱𝘩𝘢𝘴𝘦 2 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭𝘴.”   👏 Congratulations to the Step Pharma team and all co-investors for this major step forward!   #Biotech #Innovation #Oncology #VentureCapital #InnoBio2

📢 ONA Therapeutics appoints Dr. Antoine YVER as Chair of the Board. We are delighted to announce that ONA Therapeutics , a portfolio company of 𝗜𝗻𝗻𝗼𝗕𝗶𝗼 𝟮, has appointed Dr. Antoine Yver, M.D., M.Sc. as Chair of its Board of Directors. 👤 𝗔𝗯𝗼𝘂𝘁 𝗗𝗿. 𝗔𝗻𝘁𝗼𝗶𝗻𝗲 𝗬𝘃𝗲𝗿: Dr. Yver is a recognized leader in global oncology drug development, with over 35 years of experience and senior executive roles at AstraZeneca, Daiichi Sankyo, Johnson & Johnson, and Merck. He has played a pivotal role in the development and approval of 13 landmark cancer therapies, including ENHERTU®, TAGRISSO®, and LYNPARZA®, which have transformed standards of care for patients worldwide. Dr. Yver also serves as an Independent Director on the Board of Sanofi, contributing strategic and scientific insight at the highest level. 🔬 𝗔𝗯𝗼𝘂𝘁 𝗢𝗻𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀: Based in Barcelona, ONA Therapeutics is pioneering the development of first-in-class antibody-drug conjugates (ADCs) targeting aggressive and refractory solid tumors. 𝗧𝗵𝗲 𝗹𝗲𝗮𝗱 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲, 𝗢𝗡𝗔-𝟮𝟱𝟱, 𝗶𝘀 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝘁𝗼𝘄𝗮𝗿𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗳𝗼𝗿 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗶𝗻 𝗲𝗮𝗿𝗹𝘆 𝟮𝟬𝟮𝟲, with a robust pipeline addressing other high-unmet-need indications such as MSS colorectal cancer and hepatocellular carcinoma. Ona’s innovative patient-based discovery platform unlocks new biological targets, offering hope for patients with limited treatment options. We warmly congratulate Dr. Yver and the entire Ona team on this exciting new chapter. At InnoBio 2, we are proud to support visionary leaders and breakthrough science that make a real difference for patients. #InnoBio2 #Bpifrance #OnaTherapeutics #Leadership #ADC #Oncology #BiotechInnovation #PortfolioNews

🚀 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲: 𝗘𝗚 𝟰𝟮𝟳 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘀 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝘂𝗹𝘁𝘀!   We’re proud to support EG 427 , a pioneering biotech from our portfolio (Series B: €27M, Feb 2025), as they announce 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝘁𝗼𝗽𝗹𝗶𝗻𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 for their DNA medicine, 𝗘𝗚𝟭𝟭𝟬𝗔, in neurogenic bladder patients.   𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 🧬 𝟴𝟴% 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 in urinary incontinence episodes at 12 weeks (low dose cohort) 🛡️ 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝘁 𝘀𝗮𝗳𝗲𝘁𝘆 𝗽𝗿𝗼𝗳𝗶𝗹𝗲 – no systemic side effects 🎯 𝗙𝗶𝗿𝘀𝘁 𝗗𝗡𝗔 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 to locally target type-C sensory neurons 💡 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗲𝘀 EG 427’s proprietary 𝗛𝗘𝗥𝗠𝗘𝗦 𝗻𝗿𝗛𝗦𝗩-𝟭 technology platform   𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: ▪️ NDO affects 2M+ patients worldwide (SCI, MS, Parkinson’s) ▪️ Urinary incontinence represents a €69.1B annual burden in Europe alone ▪️ Opens the door to new treatments for other neurological diseases   Congratulations to the EG 427 team for this major step towards transforming care for patients with chronic neurological conditions! 👇 𝘚𝘦𝘦 𝘧𝘶𝘭𝘭 𝘱𝘳𝘦𝘴𝘴 𝘳𝘦𝘭𝘦𝘢𝘴𝘦 𝘪𝘯 𝘤𝘰𝘮𝘮𝘦𝘯𝘵 👇 #Biotech #Innovation #PortfolioCompany #DNAmedicines #Neurology #ClinicalTrials

🚀 𝗔𝗥𝗧𝗛𝗘𝘅 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝘀 𝗶𝘁𝘀 𝗦𝗲𝗿𝗶𝗲𝘀 𝗕 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝘁𝗼 $𝟴𝟳𝗠 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗥𝗡𝗔-𝗯𝗮𝘀𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀! 🔬 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗳𝗼𝗿 𝗠𝘆𝗼𝘁𝗼𝗻𝗶𝗰 𝗗𝘆𝘀𝘁𝗿𝗼𝗽𝗵𝘆 𝗧𝘆𝗽𝗲 𝟭 (𝗗𝗠𝟭) ARTHEx Biotech has successfully closed an upsized Series B round, now totaling $𝟴𝟳 𝗺𝗶𝗹𝗹𝗶𝗼𝗻! Bpifrance (Bpifrance Large Venture & Bpifrance Life Sciences Venture (InnoBio)) led the extension, joined by all existing investors: AdBio partners, CDTI Innovación - Centro para el Desarrollo Tecnológico y la Innovación, Columbus Venture Partners, EIC - European Innovation Council, Hadean Ventures, Invivo Partners, and Sound Bioventures. 💡 𝗪𝗵𝗮𝘁’𝘀 𝗻𝗲𝘅𝘁? Funding will accelerate the global clinical development of 𝗔𝗧𝗫-𝟬𝟭, a 𝗳𝗶𝗿𝘀𝘁-𝗶𝗻-𝗰𝗹𝗮𝘀𝘀 𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 for 𝗗𝗠𝟭, currently in 𝗣𝗵𝗮𝘀𝗲 𝗜/𝗜𝗜𝗮 (the 𝗔𝗿𝘁𝗵𝗲𝗺𝗶𝗥 𝗦𝘁𝘂𝗱𝘆). ATX-01 targets 𝗺𝗶𝗥-𝟮𝟯𝗯, aiming to restore MBNL protein function and address the root cause of DM1. The pipeline will also expand into other high unmet needs: muscular, CNS, and cardiac diseases. 🧬 𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 ATX-01’s dual mechanism increases MBNL and reduces toxic RNA, showing strong results in preclinical and early clinical studies. The delivery platform enables tissue-specific uptake, treating the whole disease—not just symptoms. 🙋♂️ 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗹𝗲𝗮𝗱𝘀  Large Venture: Laurent Higueret, Marine Choplain & Adrien de Saint Victor InnoBio: Benoit Barteau & Antoine Mérien 🤝 𝗜𝗻𝗻𝗼𝗕𝗶𝗼’𝘀 𝗰𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 “𝘈𝘙𝘛𝘏𝘌𝘹 𝘩𝘢𝘴 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘦𝘥 𝘢 𝘶𝘯𝘪𝘲𝘶𝘦 𝘢𝘯𝘥 𝘩𝘪𝘨𝘩𝘭𝘺 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵𝘪𝘢𝘵𝘦𝘥 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘵𝘰 𝘵𝘳𝘦𝘢𝘵 𝘋𝘔1 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴. 𝘞𝘦 𝘢𝘳𝘦 𝘦𝘢𝘨𝘦𝘳 𝘵𝘰 𝘴𝘦𝘦 𝘪𝘯𝘪𝘵𝘪𝘢𝘭 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘥𝘢𝘵𝘢 𝘪𝘯 2026.” — Benoit Barteau, Investment Director, InnoBio (Bpifrance) 👇 𝘚𝘦𝘦 𝘧𝘶𝘭𝘭 𝘱𝘳𝘦𝘴𝘴 𝘳𝘦𝘭𝘦𝘢𝘴𝘦 𝘪𝘯 𝘤𝘰𝘮𝘮𝘦𝘯𝘵 👇

🚀 𝗠𝗮𝗷𝗼𝗿 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗳𝗼𝗿 𝗨𝗿𝗼𝗠𝗲𝗺𝘀! We’re proud to share that UroMems has received both FDA IDE approval and ANSM clearance to initiate the pivotal SOPHIA2 clinical trial of UroActive®—𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝘀𝗺𝗮𝗿𝘁, 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗮𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝘂𝗿𝗶𝗻𝗮𝗿𝘆 𝘀𝗽𝗵𝗶𝗻𝗰𝘁𝗲𝗿 (𝗔𝗨𝗦) 𝗳𝗼𝗿 𝗺𝗲𝗻 𝘄𝗶𝘁𝗵 𝘀𝘁𝗿𝗲𝘀𝘀 𝘂𝗿𝗶𝗻𝗮𝗿𝘆 𝗶𝗻𝗰𝗼𝗻𝘁𝗶𝗻𝗲𝗻𝗰𝗲 (𝗦𝗨𝗜). 🔬 This breakthrough MyoElectroMechanical System is designed to adapt to patient activity and improve quality of life—without the need for manual manipulation. 🇺🇸🇫🇷 This dual regulatory green light marks a decade of innovation and a major step toward transforming care for millions of men worldwide. 💡 Bpifrance Life Sciences Venture (InnoBio) has proudly supported UroMems since 2016, backing their vision to reinvent urological care through deep tech and smart implants. 👏 Congratulations to the UroMems team and all clinical partners involved! 👉 link to the full article: https://lnkd.in/ejDKsPnB #MedTech #Urology #SmartImplants #ClinicalTrials #UroMems #Bpifrance #HealthTech

🎯 𝗖𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗶𝗻𝗴 𝗮 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗮𝘁 𝗜𝗻𝗻𝗼𝗯𝗶𝗼’𝘀 𝗔𝗻𝗻𝘂𝗮𝗹 𝗚𝗲𝗻𝗲𝗿𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 Last week, we brought together our Limited Partners—true long-term allies—to reflect on a year of progress and celebrate a standout portfolio exit. 📈  𝗟𝗣 𝗲𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁 & 𝗳𝘂𝗻𝗱 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 A heartfelt thank you to our LPs for their continued trust. We shared key results, portfolio momentum, and how their support continues to drive impact across the biotech ecosystem and for patients. 🤝  𝗘𝘅𝗶𝘁 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗔𝗺𝗼𝗹𝘆𝘁 𝗣𝗵𝗮𝗿𝗺𝗮 🔬 Origin of Eneboparatide: Initially developed by Amolyt Pharma, a clinical-stage biotech focused on rare endocrine diseases, Eneboparatide became the cornerstone of a major strategic acquisition. In 2024, AstraZeneca acquired Amolyt—part of the InnoBio 2 portfolio—for up to $1.05 billion. 🔎 Bpifrance Life Sciences Venture (InnoBio) first invested in Amolyt’s Series A in 2019, when its lead program was still preclinical. We were honored to welcome: 📍  Thierry Abribat, Founder & CEO of Amolyt Pharma, who shared the entrepreneurial journey behind eneboparatide and the acquisition by AstraZeneca. 📍 Fred Chereau, SVP Strategy & Business Development at Alexion, AstraZeneca Rare Disease, who outlined the strategic rationale behind the strategic acquisition—integrating Amolyt into AZ’s rare disease. 🥂  𝗖𝗼𝗰𝗸𝘁𝗮𝗶𝗹 & 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀 We closed the day with a vibrant networking session—LPs, co-investors, and partners exchanging ideas, deepening relationships, and sparking new opportunities. 👏 Thank you to all who joined us and continue to shape the future of health innovation with us. #Innobio #Bpifrance #HealthInnovation #VentureCapital #AmolytPharma #Alexion #RareDiseases

🚀 𝗔 𝗺𝗮𝗷𝗼𝗿 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗳𝗼𝗿 𝗖𝗼𝗿𝗪𝗮𝘃𝗲 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗵𝗲𝗮𝗿𝘁 𝗳𝗮𝗶𝗹𝘂𝗿𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁! Last week, our portfolio company CorWave has 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹𝗹𝘆 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗵𝘂𝗺𝗮𝗻 𝗶𝗺𝗽𝗹𝗮𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗶𝘁𝘀 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 #LVAD (Left Ventricular Assist Device) 𝗯𝗮𝘀𝗲𝗱 𝗼𝗻 𝘄𝗮𝘃𝗲 𝗺𝗲𝗺𝗯𝗿𝗮𝗻𝗲 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆. This first-in-human procedure marks a turning point in the treatment of advanced heart failure, offering a 𝗻𝗲𝘄 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘁𝗵𝗮𝘁 𝗺𝗶𝗺𝗶𝗰𝘀 𝘁𝗵𝗲 𝗻𝗮𝘁𝘂𝗿𝗮𝗹 𝗽𝘂𝗹𝘀𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗵𝗲𝗮𝗿𝘁 — a feat never achieved before. This success is the result of years of deep tech innovation, perseverance, and collaboration between exceptional engineers, clinicians, and investors. We are honored to support CorWave since 2013, alongside visionary partners. This is a historic moment for CorWave, for the field of mechanical circulatory support, and for patients suffering from heart failure! 👏 Congratulations to Louis de Lillers and the entire CorWave team for this incredible step forward in medtech and patient care! Philippe Boucheron #LifeSciences #MedTech #HeartFailure #Innovation #Bpifrance #CorWave #VentureCapital